Matthew Fowler

Data collected with patient-reported outcomes show that pembrolizumab, with or without bevacizumab, is associated with a favorable toxicity profile in effectively treating women with persistent, recurrent, or metastatic cervical cancer.

Preliminary findings suggest that enfortumab vedotin may be an effective treatment option for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Encouraging response rates were observed among patients with BRAF V600E–mutant metastatic colorectal cancer who received a triplet regimen of nivolumab, encorafenib, and cetuximab.

Overall, 3 objective responses were recorded from 16 eligible patients in the neuroblastoma cohort, which met the protocol-defined efficacy end point.

A poster presented at the 2020 San Antonio Breast Cancer Symposium found a trend towards less frequent care refusal when a safety net hospital introduced nurse breast navigators.

Bristol Myers Squibb recently announced that the FDA granted priority review to nivolumab plus ipilimumab in combination with chemotherapy as a first-line treatment for metastatic NSCLC.